What is Cryosa?
Cryosa is a specialized medical technology firm dedicated to addressing the global burden of sleep apnea through the development of minimally invasive therapeutic devices. Unlike traditional interventions that often suffer from low patient adherence, Cryosa's technology is engineered to eliminate the requirement for daily patient compliance. By focusing on device-based solutions that integrate seamlessly into the patient's lifestyle, the company is carving out a distinct competitive advantage in the respiratory health market. Their commitment to patient-centric design and clinical efficacy positions them as a disruptive force in the sleep medicine landscape.
How much funding has Cryosa raised?
Cryosa has raised a total of $35.7M across 3 funding rounds:
Series A
$8.3M
Series B
$21.5M
Private Equity
$6M
Series A (2020): $8.3M with participation from Santé Ventures and HOYA Corporation
Series B (2021): $21.5M led by Solas BioVentures, Santé Ventures, and HOYA
Private Equity (2025): $6M, investors not publicly disclosed
Key Investors in Cryosa
Solas BioVentures
A venture capital firm based in Tennessee that specializes in early-stage investments within the life sciences sector, including medical devices and biopharmaceuticals.
Santé Ventures
A healthcare-focused investment firm managing over $1 billion in capital, targeting innovative Medtech and Biotech companies to enhance patient health outcomes.
HOYA
A global technology company with a diversified portfolio that provides strategic backing to medical device innovators through its corporate venture arm.
What's next for Cryosa?
With the recent influx of capital, Cryosa is expected to prioritize the expansion of its clinical trial infrastructure and the refinement of its manufacturing processes to meet anticipated demand. The strategic focus will likely shift toward regulatory milestones and commercialization readiness, ensuring that their minimally invasive devices can effectively reach clinical settings. As the company matures, the integration of advanced data analytics and potential partnerships with healthcare providers will be critical in establishing a sustainable market presence. Investors remain focused on the company's ability to translate its technological innovation into improved patient outcomes and long-term enterprise value.
See full Cryosa company page
